Sign In  |  Register  |  About Sunnyvale  |  Contact Us

Sunnyvale, CA
September 01, 2020 10:10am
7-Day Forecast | Traffic

  • Search Hotels in Sunnyvale

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Reckitt Benckiser Plc ADR (OP: RBGLY )

12.02 -0.13 (-1.07%)
Streaming Delayed Price Updated: 2:28 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 251,687
Open 12.02
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 12.15
Today's Range 11.97 - 12.06
52wk Range 10.24 - 15.03
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
FDA Wants To Pull Popular OTC Decongestant Used For Common Cold Over Effectiveness Concerns
FDA proposes removing oral phenylephrine from OTC drugs for nasal congestion, citing ineffectiveness. Public comments open before a final order is issued. 
Via Benzinga
Exposures Product Safety
What You Missed On Wall Street This Past Friday
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 
Via Talk Markets

Performance

YTD
-12.58%
-12.58%
1 Month
-4.75%
-4.75%
3 Month
+7.13%
+7.13%
6 Month
+5.53%
+5.53%
1 Year
-10.83%
-10.83%

More News

Read More
Abbott Laboratories' Attractive Valuation Ranks It Among Top Large-Cap MedTech Companies, Says Analyst
Via Benzinga
Consumer Giant Reckitt Seeks Help From Investment Banks To Evaluate Options For Homecare Brands, Baby Formula
Via Benzinga
Carlyle Pays $300M For Majority Ownership In India's VLCC
Via Benzinga
British Consumer Company Reckitt Benckiser's CEO Steps Down
Via Benzinga
Abbott Labs (ABT) Stock Falls on Baby Formula Ruling. What to Know.
Via InvestorPlace
Abbott Laboratories Tumble Nearly 8% In Pre-Market After US Jury Charges $495M Penalty For Disease Causing Baby Formula
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Similac Baby Formula Maker Abbott And Reckitt Face Hundreds Of Baby Formula Lawsuits
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
What's Going On With Abbott Laboratories Stock On Friday?
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Durex Owner Reckitt Benckiser Taps Into China's Livestreaming Trend To Sell Condoms Online
Via Benzinga
NVDA Stock on Fire: Can Potential Nvidia Investors Still Get In or Will They Get Burned?
Via InvestorPlace
Reckitt's Mead Johnson Initiates Massive Recall Of 675K Cans Of Hypoallergenic Baby Formula Over Bacteria Contamination Fears
Via Benzinga
Pumpkin Spice Profits: Take a Sip of SBUX Stock Before the End of the Year
Via InvestorPlace
FDA Panel Says Popular OTC Cold, Allergy Medicine Might Be Useless - Stocks To Watch
Via Benzinga
Exposures Product Safety
3 Consumer Staples Stocks to Dump ASAP
Via InvestorPlace
Is There Collusion in the Baby-Formula Industry?: FTC Scrutinizes State Contracts Bidding Process
Via Benzinga
7 Established Stocks That Are Poised for Growth in 2023
Via InvestorPlace
Abbott Laboratories Under DOJ Investigation Into 2022 Baby Formula Plant Shutdown: Report
Via Benzinga
The Viral “Tripledemic” Opportunity
Via Talk Markets
Reckitt Sees US Baby Food Formula Crisis Persisting Till Spring: Report
Via Benzinga
The “Procter & Gamble Of The UK” Is Now On My Watchlist
Via Talk Markets
Short Volatility Alert: Reckitt Benckiser Group plc
Via Benzinga
New Starbucks CEO To Focus On Unions, Pay And Benefits As Part Of 'Reinvention' Plan
Via Benzinga
Why This Starbucks Analyst Is Surprised By New CEO Choice — And Optimistic
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Sunnyvale.com & California Media Partners, LLC. All rights reserved.